De novo minimal change disease

Markowitz, G. S.; Stemmer, CL; Bp, Croker; D'Agati, V

doi:10.1053/ajkd.1998.v32.pm9740171

Cited by 19 publications

(28 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of the cases reported as de novo MCD disease failed to meet stringent criteria for this diagnosis, and it is possible that some cases represented an early manifestation of FSGS. Markowitz et al (3) described one case and reported eight other cases that fulfilled the criteria for MCD. Truong and colleagues (4) reported five additional cases (3,5).…”

Section: Minimal Change Diseasementioning

confidence: 99%

“…Markowitz et al (3) described one case and reported eight other cases that fulfilled the criteria for MCD. Truong and colleagues (4) reported five additional cases (3,5). Other anecdotal reports of de novo MCD have been reported, including cases occurring in ABO-incompatible transplants.…”

Section: Minimal Change Diseasementioning

confidence: 99%

“…AKI occurred in three patients. On biopsy, the glomeruli are typically normal by light microscopy, although some may reveal mild focal segmental mesangial sclerosis, hypercellularity, deposition of IgM/C3, or accumulation of mononuclear inflammatory cells in some glomerular capillaries (3,5).…”

Section: Minimal Change Diseasementioning

confidence: 99%

See 2 more Smart Citations

De Novo Glomerular Diseases after Renal Transplantation

Ponticelli

Moroni

Glassock

2014

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Glomerular diseases developing in the kidney allograft are more often recurrences of the original disease affecting the native kidneys. However, in an undefined number of cases de novo, glomerular diseases unrelated to the original disease in the native kidneys can develop in the transplanted kidney. The clinical presentation and histologic features of de novo diseases are often similar to those features observed in patients with primary or secondary GN in the native kidneys. However, in transplanted kidneys, the glomerular, vascular, and tubulointerstitial changes are often intertwined with structural abnormalities already present at the time of transplant or caused by antibody-or cell-mediated allograft rejection, immunosuppressive drugs, or superimposed infection (most often of a viral nature). The pathophysiology of de novo glomerular diseases is quite variable. In rare cases of de novo minimal change disease, circulating factors increasing the glomerular permeability likely participate. Maladaptive hemodynamic changes and tissue fibrosis caused by calcineurin inhibitors or other factors may be involved in the pathogenesis of de novo FSGS. The exposure of cryptic podocyte antigens may favor the development of de novo membranous nephropathy. Many cases of de novo membranoproliferative GN are related to hepatitis C virus infection. Patients with Alport syndrome lacking antigenic epitopes in their glomerular basement membrane may develop antibodies against these glomerular basement membrane antigens expressed in the transplanted kidney. Infection may cause acute GN to have a heterogeneous clinical presentation and outcome. De novo pauci-immune GN in renal transplant is rare. Preexisting or acquired intolerance to glucose may, in the long term, cause diabetic nephropathy. The prognosis of de novo diseases depends on the type of GN, the severity of lesions caused by the alloimmune response, or the efficacy of immunosuppressive therapy. In most cases, the management of de novo glomerular diseases is empirical or elusive.

show abstract

Section: Minimal Change Diseasementioning

confidence: 99%

Section: Minimal Change Diseasementioning

confidence: 99%

See 1 more Smart Citation

De Novo Glomerular Diseases after Renal Transplantation

Ponticelli

Moroni

Glassock

2014

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Apart from this disorder, we rarely experience nephrotic‐range proteinuria just after renal transplantation. Post‐transplant nephrotic syndrome is sometimes reversible, and probably many of such cases might be associated with minimal change disease (MCD) . We present here a case of early‐post‐transplantation nephrotic syndrome caused by de novo MCD and discuss the treatment and clinical prognosis.…”

mentioning

confidence: 96%

De novo minimal change disease after ABO‐incompatible kidney transplantation

Mochizuki

Iwata

Nishikido

et al. 2012

Clinical Transplantation

View full text Add to dashboard Cite

De novo minimal change disease after ABO-incompatible kidney transplantation Mochizuki Y, Iwata T, Nishikido M, Uramatsu T, Sakai H, Taguchi T. De novo minimal change disease after ABO-incompatible kidney transplantation.Abstract: We report the clinical and pathological findings of a case of de novo minimal change disease (MCD) after ABO-incompatible living kidney transplantation. A 62-yr-old man with end-stage renal disease associated with type I diabetes received ABO-incompatible kidney transplantation from his 58-yr-old wife. Although allograft function was excellent immediately after surgery, massive proteinuria (35 g/d) appeared on post-transplantation day 5. After the allograft biopsy taken on post-transplantation day 6, he was treated with 12 cycles of plasma exchange, but the nephrotic-range proteinuria showed no remission. The biopsy specimen showed no significant pathological findings on light microscopy, but electron microscopy showed diffuse effacement of podocyte foot processes. Based on the diagnosis of de novo MCD, the patient received intravenous methylprednisolone pulse therapy, followed by high-dose steroid maintenance therapy. The steroid therapy induced complete remission of nephrotic syndrome and stable allograft function immediately, which was also maintained at one yr after the transplantation.

show abstract

“…17 This may be due to the routine exposure of transplant patients to immunosup-pressive agents that are commonly used as therapeutic agents for MCD. We also believe that patients labeled as FSGS without its light microscopic features, who respond readily to steroids or plasmapheresis and do not progress to CKD, may have MCD rather than FSGS.…”

mentioning

confidence: 99%